SSSimon Steiger

Simon Steiger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Simon Steiger has a total of 149 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Disagreement between demultiplexing methods reveals structured cell quality gradients in multiplexed single-cell data

    by Ezgi Sen, Simon Steiger, Mislav Basic, Nina Prokoph, Afzal P. Syed, Isabelle Seufert, Usama-Ur Rehman, Sabrina Schumacher, Anja Baumann, Michaela Feuring, et al.

    Background: Single-cell multi-omics profiling of hematopoietic malignancies frequently involves pooling of patient samples before library preparation to reduce costs. Demultiplexing and quality control of the resulting sequencing data depend on experimental design, sequencing depth, and computational methods. Existing approaches benchmark individual tools, auto-select a single best method, or apply majority voting. However, none systematically exploit disagreement patterns among orthogonal strategies as a diagnostic signal for cell quality. Results: We introduce Split-flow, a modular Nextflow pipeline that runs hashing-based and SNP-based demultiplexing, and transcriptome-based doublet detection in parallel. It classifies cells into quality strata through a concordance-based decision framework. Validation on multiplexed CITE-seq data from 14 multiple myeloma patients across eight Chromium channels demonstrates high reproducibility and shows that discordant cells cluster within specific cell types and quality strata. TCR clonotype cross-referencing against VDJdb confirms that concordance-based classification enriches for biologically genuine immune receptor sequences, with a 5.3-fold enrichment of confirmed public TCR sequences in the high-confidence stratum. Downsampling analysis reveals that SNP-based methods are more depth-sensitive than hash-based approaches, supporting the recommendation to combine both strategies. The framework transfers to AML samples across three assay types (snMultiome-seq, scRNA-seq, scATAC-seq), where ATAC-based demultiplexing resolves donor assignment discordance under low hashing efficiency. Conclusions: Split-flow demonstrates that combining of orthogonal preprocessing methods yields structured information about cell quality and offers a concordance-based framework that transforms this disagreement into a diagnostic signal. It introduces a preprocessing approach that can be exploited beyond hematopoietic malignancies in multiplexed single-cell applications. Graphical Highlights and main findings: Introduces Split-flow, a modular Nextflow DSL2 pipeline for preprocessing of multiplexed single-cell multi-omics sequencing data from hematopoietic malignancy samples via a post hoc concordance-based decision framework. Provides practical guidance for the experimental design of multiplexed single-cell multi-omics experiments, including the recommendation to combine antibody-based hashing with a SNP genotype reference for orthogonal demultiplexing. Reveals that SNP-based demultiplexing is more sensitive to sequencing depth than hash-based approaches, and that the combined strategy mitigates depth-dependent biases in cell-type recovery. Demonstrates that disagreement between demultiplexing methods contains structured diagnostic information about cell quality, with concordance categories reflecting genuine quality gradients in multiple myeloma CITE-seq samples. Validates the concordance framework using T cell receptor sequences as an orthogonal biological readout, with a 5.3-fold enrichment of confirmed public TCR sequences in the high-confidence stratum. Applies the preprocessing framework to AML patient samples across three assay types (snMultiome-seq, scRNA-seq, and scATAC-seq) and demonstrates that ATAC-based demultiplexing can resolve donor-assignment discordance.

  • Open Access

    Fiber intake associates with increased treatment response in patients with multiple myeloma along with changes in gut microbiome

    by Lilli Sophie Sester, Iuliia Galeeva, Juliana de Castilhos, Vadim Borisov, Anna K. Gambihler, Michael Kilian, David Vonhören, Mirco J. Friedrich, Gernot Poschet, Simon Steiger, et al.

    Key Points. High dietary fiber intake increases gut microbiome diversity and specific fibers link to MRD negativity in NDMM patients.Microbial signatures a

  • Open Access

    Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma

    by Raphael Lutz, Alexandra M. Poos, Llorenç Solé-Boldo, Lukas John, Johanna Wagner, Nina Prokoph, Marc A. Baertsch, Dominik Vonficht, Subarna Palit, Alexander Brobeil, et al.

    The bone marrow microenvironment plays a crucial role in the development of multiple myeloma. As the disease progresses, malignant myeloma cells can evolve to survive outside the bone marrow. However, the processes underlying bone marrow independence and their consequences for immune control remain poorly understood. Here, we conducted single-cell and spatial multiomics analyses of bone marrow–confined intramedullary disease and paired breakout lesions that disrupt the cortical bone. These analyses revealed a distinct cellular microenvironment and architectural features of breakout lesions, characterized by extensive areas of malignant plasma cells interspersed with lesion-specific solitary natural killer and macrophage populations, as well as focal accumulations of immune cell agglomerates. Within these agglomerates, spatially confined T cell clones expanded alongside various immune cells, coinciding with the local genomic evolution of tumor cells. These analyses identify breakout lesions as a hotspot for tumor-immune cell interactions and diversification, representing a key event in myeloma pathogenesis.


  • Open Access

    Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy

    by Raphael Lutz, Florian Grünschläger, Malte Simon, Mohamed H. S. Awwad, Marcus Bauer, Schayan Yousefian, Niklas Beumer, Lea Jopp-Saile, Anastasia Sedlmeier, Llorenç Solé-Boldo, et al.

    The long-term consequences of cancer and its therapy on the patients’ immune system years after cancer-free survival remain poorly understood. Here, we present an in-depth characterization of the bone marrow immune ecosystem of multiple myeloma long-term survivors, from initial diagnosis up to 17 years following a single therapy line and cancer-free survival. Using comparative single-cell analyses combined with molecular, genomic, and functional approaches, we demonstrate that multiple myeloma long-term survivors exhibit pronounced alterations in their bone marrow microenvironment associated with impaired immunity. These immunological alterations were frequently linked to an inflammatory immune circuit fueled by the long-term persistence or resurgence of residual myeloma cells. Notably, even in the complete absence of any detectable residual disease for decades, sustained changes in the immune system were observed, suggesting an irreversible ‘immunological scarring’ caused by the initial exposure to the cancer and therapy. Collectively, our study provides key insights into the molecular and cellular bone marrow ecosystem of long-term survivors of multiple myeloma, revealing both reversible and irreversible alterations in the immune compartment.


  • Open Access

    Progenitor-like cell type of an MLL-EDC4 fusion in acute myeloid leukemia

    by Linda C. Schuster, Afzal P. Syed, Stephan M. Tirier, Simon Steiger, Isabelle Seufert, Heiko Becker, Jesus Duque-Afonso, Tobias Ma, Seishi Ogawa, Jan-Philipp Mallm, et al.

    Linda C. Schuster, Afzal P. Syed, Stephan M. Tirier, Simon Steiger, Isabelle Seufert, Heiko Becker, Jesus Duque-Afonso, Tobias Ma, Seishi Ogawa, Jan-Philipp Mal

  • Top Cited Papers
    Open Access

    Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis

    by Alexandra M. Poos, Nina Prokoph, Moritz J. Przybilla, Jan-Philipp Mallm, Simon Steiger, Isabelle Seufert, Lukas John, Stephan M. Tirier, Katharina Bauer, Anja Baumann, et al.

    Intratumor heterogeneity as a clinical challenge becomes most evident after several treatment lines, when multidrug-resistant subclones accumulate. To address this challenge, the characterization of resistance mechanisms at the subclonal level is key to identify common vulnerabilities. In this study, we integrate whole-genome sequencing, single-cell (sc) transcriptomics (scRNA sequencing), and chromatin accessibility (scATAC sequencing) together with mitochondrial DNA mutations to define subclonal architecture and evolution for longitudinal samples from 15 patients with relapsed or refractory multiple myeloma. We assess transcriptomic and epigenomic changes to resolve the multifactorial nature of therapy resistance and relate it to the parallel occurrence of different mechanisms: (1) preexisting epigenetic profiles of subclones associated with survival advantages, (2) converging phenotypic adaptation of genetically distinct subclones, and (3) subclone-specific interactions of myeloma and bone marrow microenvironment cells. Our study showcases how an integrative multiomics analysis can be applied to track and characterize distinct multidrug-resistant subclones over time for the identification of molecular targets against them.


  • Open Access

    Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level

    by Lukas John, Alexandra M. Poos, Alexander Brobeil, Carolina Schinke, Stefanie Huhn, Nina Prokoph, Raphael Lutz, Barbara Wagner, Maurizio Zangari, Stephan M. Tirier, et al.

    In multiple myeloma spatial differences in the subclonal architecture, molecular signatures and composition of the microenvironment remain poorly characterized. To address this shortcoming, we perform multi-region sequencing on paired random bone marrow and focal lesion samples from 17 newly diagnosed patients. Using single-cell RNA- and ATAC-seq we find a median of 6 tumor subclones per patient and unique subclones in focal lesions. Genetically identical subclones display different levels of spatial transcriptional plasticity, including nearly identical profiles and pronounced heterogeneity at different sites, which can include differential expression of immunotherapy targets, such as CD20 and CD38. Macrophages are significantly depleted in the microenvironment of focal lesions. We observe proportional changes in the T-cell repertoire but no site-specific expansion of T-cell clones in intramedullary lesions. In conclusion, our results demonstrate the relevance of considering spatial heterogeneity in multiple myeloma with potential implications for models of cell-cell interactions and disease progression.


  • Dissection of gastric homeostasis in vivo facilitates permanent capture of isthmus-like stem cells in vitro

    by Aaron J. Huebner, Rebecca A. Gorelov, Ruslan Deviatiiarov, Samuel Demharter, Tobias Kull, Ryan M. Walsh, Marty S. Taylor, Simon Steiger, John T. Mullen, Peter V. Kharchenko, et al.

    The glandular stomach is composed of two regenerative compartments termed corpus and antrum, and our understanding of the transcriptional networks that maintain these tissues is incomplete. Here we show that cell types with equivalent functional roles in the corpus and antrum share similar transcriptional states including the poorly characterized stem cells of the isthmus region. To further study the isthmus, we developed a monolayer two-dimensional (2D) culture system that is continually maintained by Wnt-responsive isthmus-like cells capable of differentiating into several gastric cell types. Importantly, 2D cultures can be converted into conventional three-dimensional organoids, modelling the plasticity of gastric epithelial cells in vivo. Finally, we utilized the 2D culture system to show that Sox2 is both necessary and sufficient to generate enterochromaffin cells. Together, our data provide important insights into gastric homeostasis, establish a tractable culture system to capture isthmus cells and uncover a role for Sox2 in enterochromaffin cells.


  • Open Access

    Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomics

    by Stephan M. Tirier, Jan-Philipp Mallm, Simon Steiger, Alexandra M. Poos, Mohamed H. S. Awwad, Nicola Giesen, Nicola Casiraghi, Hana Susak, Katharina Bauer, Anja Baumann, et al.

    Virtually all patients with multiple myeloma become unresponsive to treatment over time. Relapsed/refractory multiple myeloma (RRMM) is accompanied by the clonal evolution of myeloma cells with heterogeneous genomic aberrations and profound changes of the bone marrow microenvironment (BME). However, the molecular mechanisms that drive drug resistance remain elusive. Here, we analyze the heterogeneous tumor cell population and its complex interaction network with the BME of 20 RRMM patients by single cell RNA-sequencing before/after treatment. Subclones with chromosome 1q-gain express a specific transcriptomic signature and frequently expand during treatment. Furthermore, RRMM cells shape an immune suppressive BME by upregulation of inflammatory cytokines and close interaction with the myeloid compartment. It is characterized by the accumulation of PD1+γδ T-cells and tumor-associated macrophages as well as the depletion of hematopoietic progenitors. Thus, our study resolves transcriptional features of subclones in RRMM and mechanisms of microenvironmental reprogramming with implications for clinical decision-making.


  • Open Access

    Pheno-seq – linking visual features and gene expression in 3D cell culture systems

    by Stephan M. Tirier, Jeongbin Park, Friedrich Preußer, Lisa Amrhein, Zuguang Gu, Simon Steiger, Jan-Philipp Mallm, Teresa Krieger, Marcel Waschow, Björn Eismann, et al.

    Patient-derived 3D cell culture systems are currently advancing cancer research since they potentiate the molecular analysis of tissue-like properties and drug response under well-defined conditions. However, our understanding of the relationship between the heterogeneity of morphological phenotypes and the underlying transcriptome is still limited. To address this issue, we here introduce “pheno-seq” to directly link visual features of 3D cell culture systems with profiling their transcriptome. As prototypic applications breast and colorectal cancer (CRC) spheroids were analyzed by pheno-seq. We identified characteristic gene expression signatures of epithelial-to-mesenchymal transition that are associated with invasive growth behavior of clonal breast cancer spheroids. Furthermore, we linked long-term proliferative capacity in a patient-derived model of CRC to a lowly abundant PROX1-positive cancer stem cell subtype. We anticipate that the ability to integrate transcriptome analysis and morphological patho-phenotypes of cancer cells will provide novel insight on the molecular origins of intratumor heterogeneity.